https://technologytimesnewjersey.com/article/905470633-ministers-and-members-of-parliament-at-paris-blockchain-week-2026-a-historic-signal-for-the-institutionalization-of-crypto-assets Technology Times New Jersey en PressRelease 2026-04-13T11:32:09+00:00 Ministers and Members of Parliament at Paris Blockchain Week 2026: A Historic Signal for the Institutionalization of Crypto-Assets https://ml-eu.globenewswire.com/media/ZGY4YjQzYzMtNTdkZS00YzllLTlhMDQtNTI3ZDJiOTQ4MWFlLTcwMDAyNzUwMC0yMDI2LTA0LTEzLWVu/tiny/Paris-Blockchain-Week.png https://technologytimesnewjersey.com/article/905470672-bullfrog-ai-provides-business-update-strengthened-balance-sheet-supports-continued-execution-as-company-aims-to-ramp-commercial-activity-with-global Technology Times New Jersey en PressRelease 2026-04-13T11:30:00+00:00 BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners https://ml.globenewswire.com/media/7c573a7f-e8c1-4109-b05f-11b087ee3a88/small/bfrg-logo-png.png https://technologytimesnewjersey.com/article/905470717-allogene-therapeutics-reports-interim-futility-analysis-from-pivotal-alpha3-trial-showing-58-3-mrd-clearance-with-cemacabtagene-ansegedleucel Technology Times New Jersey en PressRelease 2026-04-13T11:30:00+00:00 Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL https://ml.globenewswire.com/media/87e8712c-0741-409f-9942-c91b31e7c5e1/small/allogene-png.png https://technologytimesnewjersey.com/article/905470768-newly-published-u-s-expert-consensus-aligns-with-mediwound-s-strategy-for-chronic-wound-debridement Technology Times New Jersey en PressRelease 2026-04-13T11:30:00+00:00 Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement https://ml.globenewswire.com/media/55509183-b8b9-4da4-ae63-92c83760b5d9/small/mdwd-logo-jpg.jpg https://technologytimesnewjersey.com/article/905470770-3d-systems-accelerates-production-scale-additive-manufacturing-with-new-high-throughput-platform-and-next-generation-factory-software Technology Times New Jersey en PressRelease 2026-04-13T11:30:00+00:00 3D Systems Accelerates Production-Scale Additive Manufacturing with New High-Throughput Platform and Next-Generation Factory Software https://ml.globenewswire.com/media/c1fe14d5-b586-4dca-a30b-fdfd171ae76f/small/3d-jpg.jpg https://technologytimesnewjersey.com/article/905470793-gelatide-drops-investigated-2026-report-what-consumers-should-verify-before-buying Technology Times New Jersey en PressRelease 2026-04-13T11:23:50+00:00 Gelatide Drops Investigated (2026 Report) What Consumers Should Verify Before Buying https://ml.globenewswire.com/Resource/Download/984a2986-fdd3-4fe6-80f2-312f9d1cbc94/image2.png https://technologytimesnewjersey.com/article/905467090-from-milestone-to-momentum-kraig-biocraft-leadership-travels-to-south-east-asia-following-record-setting-1-3-metric-ton-recombinant-spider-silk Technology Times New Jersey en PressRelease 2026-04-13T11:05:00+00:00 From Milestone to Momentum: Kraig Biocraft Leadership Travels to South East Asia Following Record-Setting 1.3 Metric Ton Recombinant Spider Silk Cocoon Production Cycle https://ml.globenewswire.com/media/3cf5ab91-0822-460b-bb13-17447941c84a/small/kblb-logo-jpg.jpg https://technologytimesnewjersey.com/article/905466754-oxb-launches-fast-track-offering-for-aav-and-lentiviral-vector-platforms-accelerating-viral-vector-development-and-manufacture Technology Times New Jersey en PressRelease 2026-04-13T11:00:00+00:00 OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture https://ml-eu.globenewswire.com/media/3e905c0a-b28c-4981-ac57-745647779ad9/small/oxb-new-logo-png.png https://technologytimesnewjersey.com/article/905466795-eclipse-life-sciences-completes-enrollment-in-phase-2-study-evaluating-ec-104-for-diabetic-macular-edema-dme Technology Times New Jersey en PressRelease 2026-04-13T11:00:00+00:00 Eclipse Life Sciences Completes Enrollment in Phase 2 Study Evaluating EC-104 for Diabetic Macular Edema (DME) https://ml.globenewswire.com/media/3ed9dd28-ed00-4f7d-b5b9-1180c2c99262/small/eclipse-logo-png.png https://technologytimesnewjersey.com/article/905466864-aeluma-secures-more-than-4-million-in-contracts-for-quantum-materials-and-lasers Technology Times New Jersey en PressRelease 2026-04-13T11:00:00+00:00 Aeluma Secures More Than $4 Million in Contracts for Quantum Materials and Lasers https://ml.globenewswire.com/media/b1015780-d7ba-46d1-b327-269ba03ba2ab/small/almu-logo-jpg.jpg https://technologytimesnewjersey.com/article/905466947-nrx-pharmaceuticals-nasdaq-nrxp-announces-appointment-of-glenn-tyson-as-the-company-s-first-chief-commercial-officer Technology Times New Jersey en PressRelease 2026-04-13T11:00:00+00:00 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png https://technologytimesnewjersey.com/article/905466972-kymera-therapeutics-announces-u-s-fda-fast-track-designation-for-kt-621-a-first-in-class-oral-stat6-degrader-for-the-treatment-of-moderate-to Technology Times New Jersey en PressRelease 2026-04-13T11:00:00+00:00 Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma https://ml.globenewswire.com/media/4d3d3283-c57d-401e-9e1b-53f17e22d76b/small/kymera-logo-rgb-denim-marigold-high-res-png.png https://technologytimesnewjersey.com/article/905466973-spyre-announces-potential-best-in-class-spy001-part-a-induction-results-from-skyline-trial-in-moderate-to-severe-ulcerative-colitis-patients Technology Times New Jersey en PressRelease 2026-04-13T11:00:00+00:00 Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://technologytimesnewjersey.com/article/905466986-ocular-therapeutix-announces-additional-positive-week-52-data-from-landmark-sol-1-phase-3-trial-of-axpaxli-in-wet-amd Technology Times New Jersey en PressRelease 2026-04-13T11:00:00+00:00 Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://technologytimesnewjersey.com/article/905467081-imagenebio-announces-30-million-private-placement Technology Times New Jersey en PressRelease 2026-04-13T11:00:00+00:00 ImageneBio Announces $30 Million Private Placement https://ml.globenewswire.com/media/ccccc30d-a51c-48d7-9aec-6b542240c611/small/imagene-logo-green-jpg.jpg https://technologytimesnewjersey.com/article/905466794-ani-pharmaceuticals-announces-the-launch-of-carbamazepine-extended-release-capsules Technology Times New Jersey en PressRelease 2026-04-13T10:50:00+00:00 ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules https://ml.globenewswire.com/media/24d1d851-9075-4d6e-b22c-0c23a5ef0b36/small/ani-logo-png.png https://technologytimesnewjersey.com/article/905467025-leanzene-gummies-examined-2026-consumer-focused-breakdown-of-ingredients-claims-label-transparency Technology Times New Jersey en PressRelease 2026-04-13T10:47:40+00:00 Leanzene Gummies Examined: 2026 Consumer-Focused Breakdown of Ingredients, Claims & Label Transparency https://ml.globenewswire.com/Resource/Download/e7b8402e-d943-467a-8865-1fec7f5629cc/image2.png https://technologytimesnewjersey.com/article/905466788-offentligg-relse-af-det-endelige-resultat-for-freudenbergs-offentlige-overtagelsestilbud-til-aktion-rerne-i-nilfisk-holding-a-s Technology Times New Jersey en PressRelease 2026-04-13T10:45:07+00:00 OFFENTLIGGØRELSE AF DET ENDELIGE RESULTAT FOR FREUDENBERGS OFFENTLIGE OVERTAGELSESTILBUD TIL AKTIONÆRERNE I NILFISK HOLDING A/S https://ml-eu.globenewswire.com/media/MWUyY2QxZDUtY2RhYS00NzgyLWFjOTItOTI2YjdkMDI4M2JhLTEwMzAzNjMtMjAyNi0wNC0xMy1kYQ==/tiny/Freudenberg-Co-Kommanditgesell.png https://technologytimesnewjersey.com/article/905466791-announcement-of-the-final-result-of-freudenberg-s-public-takeover-offer-to-the-shareholders-of-nilfisk-holding-a-s Technology Times New Jersey en PressRelease 2026-04-13T10:45:07+00:00 ANNOUNCEMENT OF THE FINAL RESULT OF FREUDENBERG’S PUBLIC TAKEOVER OFFER TO THE SHAREHOLDERS OF NILFISK HOLDING A/S https://ml-eu.globenewswire.com/media/MWUyY2QxZDUtY2RhYS00NzgyLWFjOTItOTI2YjdkMDI4M2JhLTEwMzAzNjMtMjAyNi0wNC0xMy1lbg==/tiny/Freudenberg-Co-Kommanditgesell.png https://technologytimesnewjersey.com/article/905463063-regeneron-and-telix-announce-strategic-radiopharma-collaboration Technology Times New Jersey en PressRelease 2026-04-13T10:30:00+00:00 Regeneron and Telix Announce Strategic Radiopharma Collaboration https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://technologytimesnewjersey.com/article/905463143-telix-and-regeneron-announce-strategic-radiopharma-collaboration Technology Times New Jersey en PressRelease 2026-04-13T10:30:00+00:00 Telix and Regeneron Announce Strategic Radiopharma Collaboration https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://technologytimesnewjersey.com/article/905459606-four-person-dutch-startup-launches-europe-s-first-sovereign-ai-platform-beyond-the-reach-of-us-cloud-law Technology Times New Jersey en PressRelease 2026-04-13T10:00:00+00:00 Four-Person Dutch Startup Launches Europe's First Sovereign AI Platform - Beyond the Reach of US Cloud Law https://ml-eu.globenewswire.com/media/739f1abd-3c98-4be7-a742-438fd62d79f2/medium/glbnxt-team.png https://technologytimesnewjersey.com/article/905459664-bgin-blockchain-limited-announces-resolution-of-subsidiary-s-hosting-dispute-and-full-recovery-of-mining-machines Technology Times New Jersey en PressRelease 2026-04-13T10:00:00+00:00 BGIN BLOCKCHAIN LIMITED Announces Resolution of Subsidiary’s Hosting Dispute and Full Recovery of Mining Machines https://ml.globenewswire.com/media/fdca541a-9af5-43da-991a-a2268320ef04/small/bgin-jpg.jpg https://technologytimesnewjersey.com/article/905459676-springboards-launches-flint-to-break-ai-s-habit-of-predictable-boring-answers Technology Times New Jersey en PressRelease 2026-04-13T10:00:00+00:00 Springboards Launches ‘Flint’ to Break AI’s Habit of Predictable, Boring Answers https://ml.globenewswire.com/media/9e99c4c5-67a3-4f36-8700-442094c7a8d3/small/springboards-logo-black-rgb-png.png https://technologytimesnewjersey.com/article/905456087-naoo-ag-lanciert-metis-echtzeit-experimentierinfrastruktur-vervollst-ndigt-den-propriet-ren-ki-stack Technology Times New Jersey en PressRelease 2026-04-13T09:30:58+00:00 naoo AG lanciert METIS: Echtzeit-Experimentierinfrastruktur vervollständigt den proprietären KI-Stack https://ml-eu.globenewswire.com/media/f9a58220-1328-4544-8423-73fd2f08a09c/small/ https://technologytimesnewjersey.com/article/905456088-naoo-ag-launches-metis-real-time-experimentation-infrastructure-completes-proprietary-ai-stack Technology Times New Jersey en PressRelease 2026-04-13T09:30:58+00:00 naoo AG Launches METIS: Real-Time Experimentation Infrastructure Completes Proprietary AI Stack https://ml-eu.globenewswire.com/media/f9a58220-1328-4544-8423-73fd2f08a09c/small/naoo-logo-1-png.png https://technologytimesnewjersey.com/article/905451931-smart-minimalism-supreme-efficiency-cuktech-15-charging-station-makes-its-debut-in-malaysia Technology Times New Jersey en PressRelease 2026-04-13T08:40:54+00:00 Smart Minimalism, Supreme Efficiency: CUKTECH 15 Charging Station Makes Its Debut in Malaysia https://ml.globenewswire.com/media/3bf1f045-1f83-4d75-a8c5-1e9f3623347a/medium/image-1.png https://technologytimesnewjersey.com/article/905452017-berikut-adalah-terjemahan-siaran-akhbar-tersebut-ke-dalam-bahasa-melayu-minimalisme-pintar-kecekapan-ulung-stesen-pengecasan-cuktech-15-membuat Technology Times New Jersey en PressRelease 2026-04-13T08:40:54+00:00 Berikut adalah terjemahan siaran akhbar tersebut ke dalam Bahasa Melayu: Minimalisme Pintar, Kecekapan Ulung: Stesen Pengecasan CUKTECH 15 Membuat Kemunculan Sulung di Malaysia https://ml.globenewswire.com/media/3bf1f045-1f83-4d75-a8c5-1e9f3623347a/medium/image-1.png https://technologytimesnewjersey.com/article/905448383-b2prime-group-awarded-fx-solution-provider-at-wealthbriefing-2026 Technology Times New Jersey en PressRelease 2026-04-13T08:10:41+00:00 B2PRIME Group Awarded FX Solution Provider at WealthBriefing 2026 https://ml.globenewswire.com/media/546a765c-26af-4d78-9ad9-edac94fbf058/medium/b2prime.jpg https://technologytimesnewjersey.com/article/905445010-epitopea-strengthens-scientific-advisory-board-with-appointment-of-leading-authority-in-cancer-lisa-butterfield Technology Times New Jersey en PressRelease 2026-04-13T08:00:00+00:00 Epitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa Butterfield https://ml.globenewswire.com/media/e42e44d9-eec5-4ff3-a9ee-fab395efd2a8/small/epitopea-instagram-post-2-jpg.jpg https://technologytimesnewjersey.com/article/905445013-epitopea-renforce-son-comit-consultatif-scientifique-avec-la-nomination-de-lisa-butterfield-figure-de-renom-dans-le-domaine-du-cancer Technology Times New Jersey en PressRelease 2026-04-13T08:00:00+00:00 Epitopea renforce son comité consultatif scientifique avec la nomination de Lisa Butterfield, figure de renom dans le domaine du cancer https://ml.globenewswire.com/media/e42e44d9-eec5-4ff3-a9ee-fab395efd2a8/small/epitopea-instagram-post-2-jpg.jpg https://technologytimesnewjersey.com/article/905445045-over-a-third-of-americans-would-accept-twice-as-many-ads-for-cheaper-streaming Technology Times New Jersey en PressRelease 2026-04-13T08:00:00+00:00 Over a third of Americans would accept twice as many ads for cheaper streaming https://ml.globenewswire.com/media/c4b6af1c-c16f-4ab6-81f1-2cec4970ea26/small/bango-master-logo-hires-png.png https://technologytimesnewjersey.com/article/905445007-boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows Technology Times New Jersey en PressRelease 2026-04-13T07:51:00+00:00 Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows https://ml-eu.globenewswire.com/media/f121dfae-77e7-4a01-b1ef-6b757767ddab/small/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png https://technologytimesnewjersey.com/article/905432327-zoonova-ai-launches-alpha-ai-bringing-quant-driven-analytics-to-everyday-investors Technology Times New Jersey en PressRelease 2026-04-13T06:19:24+00:00 Zoonova AI Launches Alpha AI, Bringing Quant-Driven Analytics to Everyday Investors https://ml.globenewswire.com/media/2a10b2ce-54c5-459d-a2d3-c14e64893780/medium/zoonova-ai.png https://technologytimesnewjersey.com/article/905432325-a-grand-event-for-the-rubber-and-plastics-industry-cycjet-joins-you-at-chinaplas-2026 Technology Times New Jersey en PressRelease 2026-04-13T06:07:06+00:00 A Grand Event for the Rubber and Plastics Industry — CYCJET Joins You at Chinaplas 2026 https://ml.globenewswire.com/media/fdba6757-e909-4d48-9f6d-66c7d55920cd/medium/image-1.jpg https://technologytimesnewjersey.com/article/905432326-un-gran-evento-para-la-industria-del-caucho-y-el-pl-stico-cycjet-lo-invita-a-chinaplas-2026 Technology Times New Jersey en PressRelease 2026-04-13T06:07:06+00:00 Un gran evento para la industria del caucho y el plástico: CYCJET lo invita a Chinaplas 2026 https://ml.globenewswire.com/media/fdba6757-e909-4d48-9f6d-66c7d55920cd/medium/image-1.jpg https://technologytimesnewjersey.com/article/905432311-transgene-completes-patient-randomization-in-phase-2-part-of-clinical-trial-evaluating-tg4050-in-the-adjuvant-treatment-of-head-and-neck-cancer Technology Times New Jersey en PressRelease 2026-04-13T06:00:00+00:00 Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer https://ml-eu.globenewswire.com/media/a1e966ec-4255-431c-b28a-c40c9e1f8733/small/transgene-logo-rvb2026-png.png https://technologytimesnewjersey.com/article/905432314-transgene-annonce-la-fin-de-la-randomisation-des-patients-de-la-partie-phase-2-de-l-essai-clinique-valuant-tg4050-dans-le-traitement-adjuvant-des Technology Times New Jersey en PressRelease 2026-04-13T06:00:00+00:00 Transgene annonce la fin de la randomisation des patients de la partie Phase 2 de l’essai clinique évaluant TG4050 dans le traitement adjuvant des cancers de la tête et du cou https://ml-eu.globenewswire.com/media/2a0cee23-0b14-48ff-8db2-e5e966dd7bb5/small/transgene-logo-rvb2026-png.png https://technologytimesnewjersey.com/article/905432318-synox-therapeutics-announces-positive-topline-results-from-the-phase-3-tangent-study-supporting-emactuzumab-as-a-differentiated-next-generation Technology Times New Jersey en PressRelease 2026-04-13T06:00:00+00:00 SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT) https://ml.globenewswire.com/media/35d87dbe-62e3-4299-9eba-3ccdbea5d85e/small/synox-logo-jpg.jpg https://technologytimesnewjersey.com/article/905424235-press-release-sanofi-and-regeneron-s-dupixent-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous Technology Times New Jersey en PressRelease 2026-04-13T05:00:00+00:00 Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://technologytimesnewjersey.com/article/905424236-communiqu-de-presse-dupixent-de-sanofi-et-regeneron-approuv-dans-l-ue-comme-premier-m-dicament-cibl-contre-l-urticaire-chronique-spontan-e-chez Technology Times New Jersey en PressRelease 2026-04-13T05:00:00+00:00 Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://technologytimesnewjersey.com/article/905424237-wisesat-et-le-commandement-de-l-espace-des-forces-arm-es-suisses-finalisent-la-phase-pilote-et-pr-parent-la-mission-de-nouvelle-g-n-ration-wisesat-6u Technology Times New Jersey en PressRelease 2026-04-13T05:00:00+00:00 WISeSat et le Commandement de l’Espace des Forces armées suisses finalisent la phase pilote et préparent la mission de nouvelle génération WISeSat 6U prévue pour novembre 2026 https://ml-eu.globenewswire.com/media/80dae807-c8a0-4e1a-a0f0-61afcc7ae788/small/ https://technologytimesnewjersey.com/article/905424241-wisesat-and-swiss-space-command-of-the-swiss-armed-forces-complete-pilot-phase-and-prepare-next-generation-wisesat-6u-mission-planned-for-november Technology Times New Jersey en PressRelease 2026-04-13T05:00:00+00:00 WISeSat and Swiss Space Command of the Swiss Armed Forces Complete Pilot Phase and Prepare Next-Generation WISeSat 6U Mission Planned for November 2026 https://ml-eu.globenewswire.com/media/80dae807-c8a0-4e1a-a0f0-61afcc7ae788/small/wisekey-logo-png.png https://technologytimesnewjersey.com/article/905424242-wisesat-et-le-commandement-de-l-espace-des-forces-arm-es-suisses-finalisent-la-phase-pilote-et-pr-parent-la-mission-de-nouvelle-g-n-ration-wisesat-6u Technology Times New Jersey en PressRelease 2026-04-13T05:00:00+00:00 WISeSat et le Commandement de l’Espace des Forces armées suisses finalisent la phase pilote et préparent la mission de nouvelle génération WISeSat 6U prévue pour novembre 2026 https://ml-eu.globenewswire.com/media/80dae807-c8a0-4e1a-a0f0-61afcc7ae788/small/ https://technologytimesnewjersey.com/article/905424246-data-published-in-nature-communications-highlights-unique-mechanism-of-action-of-alpibectir-in-combination-with-ethionamide-alpe Technology Times New Jersey en PressRelease 2026-04-13T05:00:00+00:00 Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE) https://ml.globenewswire.com/media/37dee549-5eb0-418f-a16c-11d8422babfb/small/logo-bioversys-color-rgb-neu-for-prs-jpg.jpg https://technologytimesnewjersey.com/article/905424249-dupixent-dupilumab-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous-urticaria-csu Technology Times New Jersey en PressRelease 2026-04-13T05:00:00+00:00 Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://technologytimesnewjersey.com/article/905400865-bitcoin-poker-no-deposit-bonus-2026-bc-poker-offers-10-free-to-play-online-poker-for-real-money-with-no-cashout-cap-provably-fair-tables-and Technology Times New Jersey en PressRelease 2026-04-13T02:00:00+00:00 Bitcoin Poker No Deposit Bonus 2026: BC Poker Offers $10 Free to Play Online Poker for Real Money With No Cashout Cap, Provably Fair Tables, and Instant Crypto Withdrawals https://ml.globenewswire.com/media/328735a6-4b55-4daa-990f-5abb0fe5e067/medium/bc-poker.png https://technologytimesnewjersey.com/article/905385512-nxera-pharma-s-partner-neurocrine-biosciences-doses-first-patient-in-phase-2-trial-of-nbi-1117570-for-adults-with-schizophrenia Technology Times New Jersey en PressRelease 2026-04-12T23:30:00+00:00 Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia https://ml-eu.globenewswire.com/media/5cc74d52-c86f-4e21-8684-3496281fee15/small/nxera-master-logo-rgb-black-1-png.png https://technologytimesnewjersey.com/article/905245340-crypto-news-alphapepe-stage-12-nears-sell-out-while-xrp-price-prediction-targets-10-following-new-clarity-act-victory Technology Times New Jersey en PressRelease 2026-04-12T02:00:00+00:00 Crypto News: AlphaPepe Stage 12 Nears Sell Out While XRP Price Prediction Targets $10 Following New Clarity Act Victory https://ml.globenewswire.com/media/a8e79e81-dded-4e4a-8ce6-cbc3aebc7c1c/medium/alphapepe.jpg https://technologytimesnewjersey.com/article/905241699-unix-ai-claims-first-real-home-deployment-of-mass-produced-humanoid-robot-panther Technology Times New Jersey en PressRelease 2026-04-12T01:23:51+00:00 UniX AI Claims First Real-Home Deployment of Mass-Produced Humanoid Robot Panther https://ml.globenewswire.com/media/8605e61c-ae74-4335-bf0b-659cf666be5d/small/unix-logo-jpg.jpg https://technologytimesnewjersey.com/article/905190593-gelatine-sculpt-unveiled-does-this-pink-gelatin-trick-for-weight-loss-legit-read-gelatine-sculpt-report Technology Times New Jersey en PressRelease 2026-04-11T19:09:47+00:00 Gelatine Sculpt Unveiled: Does This Pink Gelatin Trick for Weight Loss Legit? Read Gelatine Sculpt Report! https://ml.globenewswire.com/media/46f10c1b-b2b7-48f4-9b09-e6377d6b4096/medium/gelatine-sculpt.png